Trial Profile

Pilot Study to Assess the Role of Immune Activation and Apoptosis as a Marker for Treatment Intensification With Raltegravir in Hiv-Infected Patients on Antiretroviral Therapy With Long-Term Viral Suppression and Unfavourable Immunologic Response (Discordant Patients: v+i-).

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raltegravir (Primary) ; HIV protease inhibitors; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms DISCOR-RAL

26 Sep 2012 Primary endpoint 'CD4+-cell-count' has not been met.
26 Sep 2012 Results published in AIDS.
08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com